

FcRH5a (IRTA2a)
(Soluble)
1
2
3
4
5
6
7
8
13 unique polar AA
FcRH5b
(GPI Anchor)
1
2
3
4
5
6
FcRH5c
("Full-length"/
Transmembrane)
1
2
3
4
5
6
7
8
9
104 AA
ITIM
ITIM
ITIM
Unique seq.
Shared seq.

FIG. 1A

Structure and Homology of FcRH5 Amino Acids 735 to 977

Disulfide bond

```
                                                                  *
                                  *       *       *
1   VAVPVSRPVL TLRAPGTHAA VGDLLELHCE ALRGSPLILY RFFHEDVTLG NRSSPSGGAS LNLSLTAEHS GNYSCEADNG LGAQRSETVT LYITGLTANR

                                                                                                  ^TM Domain
101 SGPFATGVAG GLLSIAGLAA GALLLYCWLS RKAGRKPASD PARSPSDSDS QEPTYHNVPA WEELQPVYTN ANPRGENVVY SEVRIIQEKK KHAVASDPRH

201 LRNKGSPIIY SEVKVASTPV SGSLFLASSA PHR
```

* Potential N-linked glycosylation site

FIG. 1B



SVT2/huFCRH5 FL
MFU FL4
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
Concentration of ab ng/ml
1G7
3B12
3G7
5A10
5F10
10A8
gD

FIG. 2A





SVT2/cy FCRH5
MFU FL4
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
ab concentration
1G7
3B12
3G7
5A10
5F10
10A8
gD

FIG. 2B



	Sample	Mean:FL4-H
■	EJM-FcRH5.1.5A10.1	1639
▒	EJM-FcRH5.7D11	977
■	EJM-FcRH5.10A8	488
▒	EJM-FcRH5.mIgG	10.3

FIG. 3A



	Sample	Mean:FL4-H
■	OPM2-FcRH5.1.5A10.1	573
▒	OPM2-FcRH5.7D11	356
■	OPM2-FcRH5.10A8	256
▒	OPM2-FcRH5.mIgG	6.43

FIG. 3B



5F1.1
% of Max
FL4-H
7D11 4ug/ml
Sub clone sup 4ug/ml
IgG1 4ug/ml

FIG. 3D



5A10.1
% of Max
FL4-H
7D11 4ug/ml
Sub clone sup 4ug/ml
IgG1 4ug/ml

FIG. 3C



6D2.2
% of Max
FL4-H
7D11 4ug/ml
Sub clone sup 4ug/ml
IgG1 4ug/ml

FIG. 3F



3G7.1
% of Max
FL4-H
7D11 4ug/ml
Sub clone sup 4ug/ml
IgG1 4ug/ml

FIG. 3E



Del
0
5
10
15
20
25
30
35
1H2.2
1H2.5
1F4.1
1F4.2
1G7.2
1G7.4
1C8.1
1C8.3
2H7.3
2H7.4
2D10.3
2D10.4
3A4.2
3A4.4
3G7.1
3B12.1
3B12.2
4G8.1
5F1.1
5F1.2
5A10.1
3F10.2
3F10.7
3C10.1
3C10.3
3C10.4
3C10.6
3G3.4
3G3.5
3G3.6
3G3.7
6D2.2
3B12.1.1
3B121.3
3G7.1.3
3G7.1.4
5A10.1.3
5A10.1.4
5F1.1.5
5F1.1.7
gD
10A8
media

FIG. 4A



MFU FL2
0
5
10
15
20
25
30
35
40
45
50
1H2.2
1H2.5
1F4.1
1F4.2
1G7.2
1G7.4
1C8.1
1C8.3
2H7.3
2H7.4
2D10.3
2D10.4
3A4.2
3A4.4
3G7.1
3B12.1
3B12.2
4G8.1
5F1.1
5F1.2
5A10.1
3F10.2
3F10.7
3C10.1
3C10.3
3C10.4
3C10.6
3G3.4
3G3.5
3G3.6
3G3.7
6D2.2
3B12.1.1
3B121.3
3G7.1.3
3G7.1.4
5A10.1.3
5A10.1.4
5F1.1.5
5F1.1.7
gD
10A8
media
WT
MFU=50-160

FIG. 4B



1.00
0.75
0.50
0.25
0.00
-0.25
OD 650
0.0001
0.001
0.01
0.1
1
Concentration of ab ng/ml
1G7
2H7
3A4
3B12
3G7
5A10
5F1

FIG. 5A



Subclone Sups on Hu B-Cells (CD19+)
B-cells
Geo Mean FL4
0
10
20
30
40
50
60
70
80
90
Subclone Sup
1H2.2
1H2.5
1F4.1
1F4.2
1G7.2
1G7.4
1C8.1
1C8.3
2H7.3
2H7.4
2D10.3
2D10.4
3A4.2
3A4.4
3G7.1
3B12.1
3B12.2
4G8.1
5F1.1
5F1.2
5A10.1
3B12.1.1
3B121.3
3G7.1.3
3G7.1.4
5A10.1.3
5A10.1.4
5F1.1.5
5F1.1.7
3F10.2
3F10.7
3C10.1
3C10.3
3C10.4
3C10.6
3G3.4
3G3.5
3G3.6
3G3.7
No Ab
a-gd mAb
a-FCRH1
a-FCRH2
a-FCRH3
a-FCRH4
mAb 10A8

FIG. 5B



FCRH1
400
350
300
250
200
150
100
50
0
1H2
1F4
1G7
1B8
1C8
1H11
1C12
2H7
2D10
3G3
3A4
3C5
3G7
3C10
3F10
3B12
3D12
4D4
4G8
4H8
5F1
5H9
5A10
5B12
6D2
GD

FIG. 6A



FCRH2
1200
1000
800
600
400
200
0
1H2
1F4
1G7
1B8
1C8
1H11
1C12
2H7
2D10
3G3
3A4
3C5
3G7
3C10
3F10
3B12
3D12
4D4
4G8
4H8
5F1
5H9
5A10
5B12
6D2
GD

FIG. 6B



FCRH3
20
18
16
14
12
10
8
6
4
2
0
1H2
1F4
1G7
1B8
1C8
1H11
1C12
2H7
2D10
3G3
3A4
3C5
3G7
3C10
3F10
3B12
3D12
4D4
4G8
4H8
5F1
5H9
5A10
5B12
6D2
GD

FIG. 6C



FCRH4
100
90
80
70
60
50
40
30
20
10
0
1H2
1F4
1G7
1B8
1C8
1H11
1C12
2H7
2D10
3G3
3A4
3C5
3G7
3C10
3F10
3B12
3D12
4D4
4G8
4H8
5F1
5H9
5A10
5B12
6D2
GD

FIG. 6D



NK Cells
0
5
10
15
20
25
30
35
1H2.2
1H2.5
1F4.1
1F4.2
1G7.2
1G7.4
1C8.1
1C8.3
2H7.3
2H7.4
2D10.3
2D10.4
3A4.2
3A4.4
3G7.1
3B12.1
3B12.2
4G8.1
5F1.1
5F1.2
5A10.1
3B12.1.1
3B121.3
3G7.1.3
3G7.1.4
5A10.1.3
5A10.1.4
5F1.1.5
5F1.1.7
No Ab
a-gd mAb
a-FcRH1
a-FcRH2
a-FcRH3
a-FcRH4
mAb 10A8

FIG. 7



%killing 293/FcRH5
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10 100 1000 10000
bis fab concentration
5A10
1G7
2H7
3G7
5F1
10A8
Her2

FIG. 8A





%killing 293/FcRH5
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10 100 1000 10000
bis fab concentration
6D2
3B12
3C10
3F10
10A8
Her2

FIG. 8B




	EC50 ng/ml
2H7 TDB	5.0
2H7 BisFab	2.5
3G7 TDB	1.8
3G7 Bis Fab	1.8

FIG. 8C



	EC50 ng/ml
5A10 TDB	2.7
2H7 BisFab	2.1

FIG. 8D



	EC50
2H7.TDB	273 pM
2H7.BisFab	285 pM
3G7.TDB	335 pM
3G7.BisFab	190 pM

FIG. 9A




FIG. 9B